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BACKGROUND: The low probability of curing high-risk prostate cancer (PC) with local therapy suggests the need to study modality of
therapeutic approaches. To this end, a prospective phase II trial of neoadjuvant docetaxel (D) and complete androgen blockade
(CAB) was carried out in high-risk PC patients. The primary end point was to detect at least 10% of pCRs after chemohormonal
treatment.
METHODS: Patients with T1c–T2 clinical stage with prostate-specific antigen (PSA) 420ngml
 1 and/or Gleason score X7( 4þ3)
and T3 were included. Treatment consisted of three cycles of D 36mgm
 2 on days 1, 8 and 15 every 28 days concomitant with
CAB, followed by radical prostatectomy (RP).
RESULTS: A total of 57 patients were included. Clinical stage was T1c, 11 patients (19.3%); T2, 30 (52.6%) and T3, 16 (28%) patients.
Gleason score was X7( 4þ3) in 44 (77%) patients and PSA 420ngml
 1 in 15 (26%) patients. Treatment was well tolerated with
51 (89.9%) patients completing neoadjuvant therapy together with RP. The rate of pCR was 6% (three patients). Three (6%)
additional patients had microscopic residual tumour (near pCR) in prostate specimen. With a median follow-up of 35 months, 18
(31.6%) patients presented PSA relapse.
CONCLUSION: Short-term neoadjuvant D and CAB induced a 6% pCR rate, which is close to what would be expected with ADT
alone. The combination was generally well tolerated.
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Patients with high-risk localised or locally advanced prostate
cancer (PC) are defined by prostate-specific antigen (PSA)
420ngml
 1, Gleason score 47 and clinical stage T3/T4. In this
group of patients, reported rates of disease-free survival (DFS)
after local therapy range from 30 to 50% (D’Amico, 2007; Joniau
and Van Poppel, 2008). In this context, the role of systemic
adjuvant or neoadjuvant therapy has been investigated with the
aim of improving the results obtained with local therapy alone.
In this regard, the use of early and prolonged androgen ablation
in association with radiation therapy delays disease progression
and improves overall survival. Randomised trials have also shown
that long-term hormonal therapy is superior to short-term
hormonal therapy in association with radiation therapy. However,
long-term androgen suppression is associated with an increased
risk of toxicity (Hanks et al, 2003; D’Amico et al, 2008; Roach et al,
2008; Sanda et al, 2008). In contrast, the use of neoadjuvant
hormonal therapy alone before prostatectomy has shown reduc-
tion of positive surgical margins but results in anecdotal pCRs.
Moreover, no benefit to patient outcome was observed in
randomised trials of neoadjuvant hormonal therapy and no
differences between short- and long-term treatments were reported
(Kumar et al, 2006).
More recently, on the basis of the evidence that docetaxel (D)
has clinical activity and increases survival in patients with
metastatic hormone refractory PC (Petrylak et al, 2004; Tannock
et al, 2004; Berthold et al, 2008), this drug has been tested as
neoadjuvant therapy in high-risk localised PC. In neoadjuvant
studies including a limited number of patients and using different
chemotherapy schedules, D alone had clinical activity but no pCRs
were reported (Dreicer et al, 2004; Febbo et al, 2005; Magi-Galluzzi
et al, 2007).
In this study, we sought to study the potential role of the
combination of chemotherapy and hormonal treatment in a
neoadjuvant setting. In particular, we explored the combination
of D and hormonal therapy with the objective of targeting both the
androgen-dependent and -independent cell subpopulations that
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smay coexist at the primary tumour and/or micrometastatic
disease. We report here the activity of weekly D in combination
with short-term (3 months) CAB before radical prostatectomy
(RP) in high-risk localised PC patients. We chose this schedule on
the basis of the low toxicity profile of weekly D and short-term
CAB, and because the duration of neoadjuvant therapy would not
significantly delay local therapy. The main objective of the study
was to determine the rate of pCR of the combined therapy.
PATIENTS AND METHODS
Study design
The study was a multicentre non-randomised phase II trial. The
main objective was to determine the percentage of pCR achieved
with D together with complete androgen blockade (CAB) in
patients with high-risk PC. Secondary objectives were to determine
the toxicity and clinical activity of the study combination. The
study was approved by the Spanish Ministry of Health; and by the
internal review board and ethics committee of each participating
institution.
Patients
Inclusion criteria were histologically confirmed adenocarcinoma of
the prostate with any of the following risk criteria: (1) clinical stage
T3 or (2) clinical stage T1c or T2 with serum PSA 420ngml
 1
and/or Gleason score sum of 8, 9 or 10; or a Gleason sum of 7 with
a predominant form of 4 (i.e. Gleason score 4þ3¼7). Patients had
to be suitable candidates for RP. An Eastern Cooperative Oncology
Group performance status of 0–1 was required. Normal blood cell
count and biochemistry were required. Patients had to sign an
informed consent to be included in the study.
Treatment and monitoring
Patients were treated with D 36mgm
 2 on days 1, 8 and 15 every
28 days, for three cycles, together with CAB consisting of
flutamide, 250mg p.o. three times per day, starting day 1, for 12
weeks and trimestral goserelin, a single s.c. dose of 10.8mg on day
15. Pre-medication with oral dexamethasone consisted of 8mg
dose 1h before every D administration. Anti-emetics were allowed
at the discretion of the treating physician. Baseline study consisted
of clinical anamnesis, complete blood count and biochemistry,
serum testosterone, physical exam, digital rectal examination,
endorectal ultrasound, thorax X-ray, bone gammagraphy, and
abdominal and pelvic CT scan or MRI. Patients were assessed for
toxicity on days 1, 8 and 15 of every cycle, before chemotherapy
administration. Patients were allowed one dose-level reduction of
D for toxicity. Every 4 weeks, digital rectal examination, complete
blood cell count and chemistries, serum testosterone and PSA level
measurement were repeated for all the patients. Pelvic CT scan
or MRI was repeated before RP. If severe toxicity or disease
progression were documented during the treatment period,
patients were withdrawn from the study and were offered local
therapy with RP or radiotherapy. In patients who completed
neoadjuvant therapy, RP was performed 2–4 weeks after the end of
systemic therapy. The administration of immediate postoperative
radiation therapy was allowed in patients with XpT3 and/or
positive surgical margins. Adjuvant hormonal therapy was allowed
in case of histologically confirmed lymph node involvement. After
surgery, patients were followed with clinical anamnesis and PSA
every 3 months during the first 2 years, every 6 months during the
next 3–5 years and annually thereafter. Prostate-specific antigen
response was evaluated before RP, following the PSA response
criteria (Bubley et al, 1999). Prostate-specific antigen relapse was
considered as a PSA 40.4nmml
 1 after RP, confirmed in at least
two determinations (Heidenreich et al, 2008).
Pathologic evaluation
All pathologists followed the same procedures to assess pathologic
response to chemotherapy. Processing and analysis of tumour
samples were standardised for all participating centres. Multiple
sections of the whole surgical specimen were processed. A pCR was
defined as complete eradication of the tumour, evidenced by the
absence of residual neoplastic cells in the surgical specimen
determined by haematoxylin and eosin staining. We considered
that the postoperative Gleason score may be altered by the effects
of neoadjuvant therapy and that its evaluation may differ by
pathologist. For that reason, we did not report these data. Frozen
and paraffin-embedded prostatectomy samples were prospectively
harvested for future correlative scientific studies.
Statistical analysis
Considering that the reported percentages of pCR obtained with
3-month hormonal therapy alone range from 0 to 4%, we chose as
the primary end point a 10% or more pCR rate after chemo-
hormonal treatment. The sample size was calculated by the Gehan
method (a error of 0.05 and b error of 10%) (Hanfelt et al, 1999).
A three-stage design was specified. If at least one pCR was
observed in the first 22 patients included, the study would enrol an
additional 20 patients. If at least two pCRs were observed, the
sample size would again be increased up to 57 patients. Median
time to PSA progression, clinical progression and survival was
considered since the time of inclusion in the study until PSA
progression, clinical progression or death occurred, and was
calculated by the Kaplan–Meier method (Kaplan and Meier, 1975).
RESULTS
Patient characteristics
From August 2004 to July 2006, 57 patients were included in the
study. Patient characteristics are shown in Table 1. All patients
were node negative and free from metastatic disease by imaging
studies. Median age was 66 (range, 66–68.3). Clinical stage was T1c
in 11 patients (19.3%), T2 in 30 (52.6%) and T3 in 16 (28%)
patients. The Gleason score was X7( 4þ3) in 44 (77%) patients,
and PSA was 420 in 15 (26%) patients. Median PSA was 9.7
(range, 0.6–90.8). Thirty-three patients (58%) presented one risk
factor, 21 (36%) two and 3 (5%) had three risk factors.
Neoadjuvant therapy
A total of 161 cycles of D were administered, with a median of
three cycles per patient. Four patients received one chemotherapy
cycle and two patients received two cycles. The remaining patients
completed the planned therapy. Dose reduction of D was
performed in 10 patients (17.5%). In 15 patients (26.3%) flutamide
was discontinued. All patients received the planned single dose
of goserelin. Median relative dose intensity was 96% for D and
90% for flutamide. Toxicities are shown in Table 2. Grades 3 and 4
toxicities were diarrhoea and liver abnormalities, mainly attributed
to flutamide. Flutamide was chosen because it was the most widely
used anti-androgen by the investigators in clinical practice at the
time of trial design. In the light of the observed hepatotoxicity with
the combination of D and flutamide in this study, we suggest that
further combination studies should consider replacing flutamide
with other anti-androgens that have fewer liver side effects.
Prostate-specific antigen response was evaluated in 51 of 57
patients after chemo-hormonal therapy and before RP. One patient
experienced PSA stabilisation, 24 (47%) had partial PSA response
and in 26 (51%) PSA became undetectable. None of the patients
had PSA progression during neoadjuvant therapy. The PSA
response rate was 93% (range, 86–99%, with a 95% CI).
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sSurgery
A total of –51 (89.9%) patients completed the three cycles of D and
hormone therapy and underwent RP. Bilateral pelvic lymphade-
nectomy was performed in 49 of the 51 patients who underwent
RP. Median number of extracted lymph nodes was 6 (range,
1–15). Five patients did not complete the planned neoadjuvant
treatment because of toxicity (one underwent RP and the rest were
treated with radiation therapy plus hormonal therapy). One patient
refused surgery after completing the neoadjuvant therapy. Of the
51 patients who underwent RP, 1 experienced a urinary fistula. No
other major surgical complications were observed.
Pathological response
Of the 51 patients evaluated for pathological response, in 33
(64.7%) the surgical margins were negative and in 27 (53%) no
extraprostatic involvement was observed. Lymph node involve-
ment was detected in two (3.9%) patients. In three (6%) patients,
no evidence of tumour cells was detected in prostatectomy
specimens. They were counted as having a pCR. In three additional
patients (6%), there was only residual microscopic tumour
(Table 3). Pathological stage was pT0 in 3 patients (5.9%), pT2
in 29 (57%) and pT3 in 19 (37%) patients. No statistically
significant correlation was observed between pathological response
and clinical stage, Gleason score and PSA level (data not shown).
Outcome
Median follow-up time was 35 months (range, 23–47). In only one
patient, the first PSA determination after RP was X0.4ngml
 1.
Sixteen (29%) patients received post-operative radiation therapy
for positive surgical margins, extraprostatic involvement or PSA
relapse. The patient with pathological lymph node involvement
started immediate hormonal therapy after surgery.
During the follow-up, 18 (31.6%) patients had a biochemical
relapse and 2 had a clinical relapse. None of the 3 patients with pCR
relapsed. Among the 18 patients who had a biochemical relapse, 7
had received adjuvant radiation therapy. Conversely, of the total 16
patients who received adjuvant radiation therapy, 7 (43.7%) had a
biochemical relapse, a finding that is consistent with the selection of
poor prognosis patients for adjuvant radiation therapy. However, the
size of the study, the present follow-up and the variations on post-
surgical management of the patients limit the possibility of any
meaningful results in terms of recurrence rates.
DISCUSSION
In this study, we report that a combination of weekly D plus a
short-term CAB is safe and induces a modest pCR rate in high-risk
localised PC. However, the study did not meet the primary end
point (pCR rate was 6%) and there was no relationship between
response and other risk factors (i.e. Gleason, PSA, T stage),
suggesting that the addition of D to hormonal therapy did not have
a significant effect on pCR.
Earlier randomised studies of neoadjuvant hormonal therapy
showed a lower incidence of positive surgical margins and lymph
node metastasis, but without impact on patient outcome. In early
reports, the pCR rates ranged from 5 to 15%. However, no
relationship between pathological response to neoadjuvant
hormonal therapy and patient survival was observed. In studies
using short-term neoadjuvant hormonal therapy (3 months, as
used in this study), serum PSA did not reach undetectable levels in
most patients and pCRs were rarely observed (0–4%), although
tumour down-staging and reduction of positive surgical margins
were reported (Gleave et al, 1996; Prezioso et al, 2004; Klotz et al,
2005; Pendleton et al, 2007; D’Amico et al 2008).
Likewise, neoadjuvant D alone has shown activity but not pCRs
in high-risk PC patients. In a phase II trial of D administered on
a weekly schedule for 6 weeks before RP, pathologic analysis
revealed residual carcinoma in all cases. Three patients (11%) had
Table 1 Patients characteristics
Total number 57 patients
Median age (years) 68.3 (range, 49–75)
ECOG
0 51 (80%)
1 5 (8.4%)
Unknown 1 (0.6%)
Clinical stage
T1 11 (19%)
T2 30 (53%)
T3 16 (28%)
Gleason score
o6 3 (5%)
7 28 (48%)
8 15 (27%)
9 11 (20%)
PSA (ngml
 1)
420 15 (26%)
o20 42 (74%)
Median PSA (ngml
 1) 9.7 (range, 0.6–90.8)
Number of risk factors
a
1 33 (58%)
2 21 (36%)
3 3 (5%)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; PSA¼prostate-
specific antigen.
aRisk factors: T3, Gleason X7 (4+3), PSA 420ngml
 1.
Table 2 Toxicity
Toxicity
Grade 1,
n (%)
Grade 2,
n (%)
Grade 3,
n (%)
Grade 4,
n (%)
Anaemia 42 (73) 1 (2)
Plaquetopenia 4 (7) 1 (2)
Neutropenia 10 (18) 4 (7)
Fluid retention 1 (2)
Alopecia 11 (20) 2 (4)
Nail toxicity 9 (16)
Rash 2 (4) 2 (4)
Mucositis 3 (6) 2 (4)
Diarrhoea 13 (23) 7 (12) 4 (7) 1(2)
Nausea/vomiting 10 (18) 8 (14)
Hepatic 10 (18) 12 (21) 7 (12)
Fatigue 13 (23) 8 (14)
Neurotoxicity 4 (7)
Table 3 Clinical characteristics of patients with pCR and near pCR
(microscopic residual disease) in surgical specimens
Clinical
T stage
Preoperative
PSA (ngml
 1)
Gleason
score
Pathological
response
T1c 9.38 9 (4+5) pRC
T2a 4.76 8 (4+4) pRC
T2a 3.18 7 (4+3) pRC
T3 0.61 7 (4+3) Near pRC
T3 13 7 (3+4) Near pRC
T2b 4.3 8 (3+5) Near pRC
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sorgan-confined disease, and 26 (93%) achieved an undetectable
PSA. At a median follow-up of 23 months, 20 patients were disease
free with no additional therapy (Dreicer et al, 2004). Another
group studied 19 patients treated with neoadjuvant weekly D for 6
months and they did not report any pCR. At 26.5 months of follow-
up, 81% of patients were free of biochemical relapse (Febbo et al,
2005). In another trial, 28 patients were treated with 6 weekly doses
of D (40mgm
 2) by RP. No pCRs were observed. At a median
follow-up of 49.5 months, 12 patients (43%) remained clinically
and biochemically free of disease with no additional therapy
(Magi-Galluzzi et al, 2007). Combination of D with other agents
such as mitoxantrone (Garzotto et al, 2006) or capecitabine
(Friedman et al, 2008) has also failed to show pRC.
This trial and a few studies published earlier tested the
combination of neoadjuvant D with hormonal therapy in high-
risk PC. One group treated 20 patients with a sequential schedule
of LHRH analogue until the PSA nadir and then continued
hormonal therapy with estramustine and D. They found that one
(5%) patient had no residual tumour (pT0) and six (32%) had
residual cancer in at least 10% of the surgical specimen. At 53
months of follow-up, 42% of the patients were disease free. In that
trial, organ-confined disease (P¼0.022), residual cancer in p10%
of the surgical specimen (P¼0.007) and no seminal vesicle
invasion (P¼0.001) correlated with DFS (Prayer-Galetti et al,
2007). A large phase II multicentre study of 6 months of androgen
ablation with weekly D included 72 patients with high-risk PC,
with 64 of them completing protocol therapy. Two (3%) pCRs and
a 30% biochemical relapse rate at 42.7 months of follow-up were
reported (Chi et al, 2008).
To the best of our knowledge, this is the first study to explore
the feasibility and activity of 3 months of maximum androgen
blockade associated with weekly D in high-risk PC before
prostatectomy. The 6% of pCR in our study is in the range of
the previously reported studies with longer duration therapy with
D and hormonal therapy (Prayer-Galetti et al, 2007; Chi et al,
2008). In the whole series, 47% of patients had pathological organ-
confined disease, similar to expected rates with neoadjuvant
hormonal therapy alone. We would like to note that 72% of
patients with clinically organ-confined disease (T1 or T2) were
included. Without any neoadjuvant therapy, 27–35% of patients
with these clinical T stages are expected to have pathological
organ-confined disease. The rate of positive surgical margins in
our series was 35%, similar to the rates expected with neoadjuvant
hormonal therapy alone (Gleave et al, 1996; Prezioso et al, 2004;
Klotz et al, 2005; Pendleton et al, 2007; D’Amico et al, 2008). This
result further suggests that D added little to hormonal therapy. In
our series, only one patient had pathological lymph node
involvement. This rate (3.9%) of lymph node disease was
considerably lower than what is expected (close to 20%) in
extended lymph node dissection in high-risk patients (Heidenreich
et al, 2007; Burkhard and Studer, 2008). There are several potential
explanations for this discrepancy, including lymph node sampling
error or inclusion of not truly high-risk patients. The study
included patients with either clinical stage T3 disease (28%), or
clinical stage T1c or T2 with adverse PSA and/or Gleason score
(72%), as detailed in Patients and methods section. We cannot rule
out that our population, taken together, had less advanced disease
than other reported series because of the selection criteria (other
studies included basically cT3/T4 disease) or other variations
among different studies. It is also tempting to speculate that the
addition of D to hormonal treatment might have had an impact on
lymph node status. However, this possibility cannot be addressed
in our study and, in fact, other relevant end points (pCRs, surgical
margins) do not support this concept. We would like to point out
that the fact that the addition of D did not increase the rate of
pCR compared with hormonal therapy does not completely rule
out a possible benefit in micrometastatic disease and long-term
outcome. As mentioned earlier, no relationship between the
percentage of pCRs to neoadjuvant hormonal treatment and
patient outcome has been reported to date (Gleave et al, 1996;
Prezioso et al, 2004; Klotz et al, 2005; Pendleton et al, 2007;
D’Amico et al, 2008). However, in an earlier study of neoadjuvant
D and hormone therapy, a correlation between the presence of
residual tumour in o10% of the surgical specimen and a better
DFS was observed (Prayer-Galetti et al, 2007). In our trial, long-
term outcome was not objective and the limited sample size as well
as the fact that a significant percentage of patients received
adjuvant radiation therapy might further limit the correct
interpretation of any possible effect on outcome.
Another issue that needs to be considered is the schedule of
D used in our and other studies of neoadjuvant therapy. The
administration of D every 3 weeks is superior in terms of response
and overall survival than weekly D in metastatic hormone-
independent PC (Tannock et al, 2004). When this trial was
designed, these data were not well established and the weekly D
schedule was chosen because of its low toxicity profile. However,
hormone-naive localised high-risk PC might be a biologically
different disease for which the optimal dose and schedule of D,
if any, have not been determined yet.
Another unresolved question is the timing of combination
therapy. In a pre-clinical PC model, simultaneous androgen
deprivation with paclitaxel was more effective than a sequential
schedule (Eigl et al, 2005). In another preclinical study,
immunodeficient mice bearing human LNCaP prostate tumours
were treated with D and/or surgical castration applied singly,
concurrently or in different sequences. Docetaxel followed by
castration improved outcomes in LNCaP PC-bearing mice,
compared with simultaneous therapy (Tang et al, 2006). The
optimal timing and scheduled combination of hormone and
chemotherapy have not been clinically tested in PC.
In conclusion, the combination of D and CAB used in our trial
failed to meet the primary end point of at least 10% of the pCR rate.
Moreover, the percentage of positive margins and the rate of PSA
relapse did not differ from the results of the trials with neoadjuvant
hormonal therapy alone. Therefore, our data do not support the
concept of neoadjuvant D-based chemotherapy in combination with
hormonal therapy as a valuable strategy, at least in terms of effects in
the primary tumour, in high-risk PC. The results of an ongoing
randomised trial (Eastham et al, 2003) on neoadjuvant hormonal
therapy in combination with D may help to further define the
possible role, if any, of this agent in high-risk PC patients.
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